Baudax Bio, Inc.
BXRXQOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$4359
P/E Ratio—
52W High$0.0001
52W Low$0.00001
Baudax Bio, Inc. (BXRXQ) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BXRXQ · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.27M | $1.08M | $0.49M | $0.00M | $0.00M |
| Cost of Revenue | $7.01M | $2.44M | $1.73M | $0.00M | $0.00M |
| Gross Profit | ($5.74M) | ($1.36M) | ($1.24M) | $0.00M | $0.00M |
| Gross Margin %(computed) | -452.32% | -126.39% | -251.32% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $3.89M | $3.13M | $9.09M | $20.06M | $35.58M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $27.01M | $29.45M |
| Total Operating Expenses | $51.07M | $17.64M | $73.55M | $32.52M | $73.53M |
| Operating Income | ($56.81M) | ($19.01M) | ($74.79M) | ($32.52M) | ($73.53M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $2.30M | $1.36M | $0.00M | $0.00M |
| Income Before Tax | ($58.80M) | ($19.77M) | ($76.10M) | ($32.56M) | ($73.67M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($58.80M) | ($19.77M) | ($76.10M) | ($32.56M) | ($73.67M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-177.30 | $-361.16 | $-5714.80 | $-4872.07 | $-11361.35 |
| Wtd Avg Shares | 0.33M | 0.05M | 0.01M | 0.01M | 0.01M |
| EBITDA | ($33.58M) | ($49.56M) | ($72.19M) | ($32.08M) | ($64.64M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Baudax Bio, Inc. data
About Baudax Bio, Inc. (BXRXQ) Income Statement
Baudax Bio, Inc. (BXRXQ) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, BXRXQ reported revenue of $0.00B, gross profit of ($0.01B) (gross margin -452.32%), and net income of ($0.06B) — a net profit margin of -4633.18%.
Frequently asked questions
BXRXQ · 4 questionsBaudax Bio, Inc. (BXRXQ) reported revenue of $0.00B for 2022, up 17.5% year-over-year.
BXRXQ revenueBXRXQ salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09